AU1364799A - Use of aliphatic polyamines for reducing oxalate - Google Patents

Use of aliphatic polyamines for reducing oxalate

Info

Publication number
AU1364799A
AU1364799A AU13647/99A AU1364799A AU1364799A AU 1364799 A AU1364799 A AU 1364799A AU 13647/99 A AU13647/99 A AU 13647/99A AU 1364799 A AU1364799 A AU 1364799A AU 1364799 A AU1364799 A AU 1364799A
Authority
AU
Australia
Prior art keywords
aliphatic polyamines
reducing oxalate
oxalate
reducing
polyamines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13647/99A
Other languages
English (en)
Inventor
Stephen Randall Holmes-Farley
W. Harry Mandeville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geltex Pharmaceuticals Inc
Original Assignee
Geltex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharmaceuticals Inc filed Critical Geltex Pharmaceuticals Inc
Publication of AU1364799A publication Critical patent/AU1364799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU13647/99A 1997-11-05 1998-10-26 Use of aliphatic polyamines for reducing oxalate Abandoned AU1364799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/964,956 US5985938A (en) 1997-11-05 1997-11-05 Method for reducing oxalate
US08964956 1997-11-05
PCT/US1998/022606 WO1999022744A1 (en) 1997-11-05 1998-10-26 Use of aliphatic polyamines for reducing oxalate

Publications (1)

Publication Number Publication Date
AU1364799A true AU1364799A (en) 1999-05-24

Family

ID=25509224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13647/99A Abandoned AU1364799A (en) 1997-11-05 1998-10-26 Use of aliphatic polyamines for reducing oxalate

Country Status (10)

Country Link
US (3) US5985938A (enExample)
EP (2) EP1645278A3 (enExample)
JP (1) JP4452402B2 (enExample)
AR (1) AR016001A1 (enExample)
AU (1) AU1364799A (enExample)
CA (1) CA2349620C (enExample)
DE (1) DE69833134T2 (enExample)
TW (1) TW585772B (enExample)
WO (1) WO1999022744A1 (enExample)
ZA (1) ZA989671B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
GB9927088D0 (en) * 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
DE10028167B4 (de) * 2000-06-09 2004-02-19 Storch, Rüdiger, Dr. Verwendung von Calciumsalzen zur Entgegenwirkung der Bildung von Oxalatharnsteinen
WO2002085378A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Low salt forms of polyallylamine
ATE380553T1 (de) * 2001-04-18 2007-12-15 Genzyme Corp Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
CN1509180A (zh) * 2001-04-18 2004-06-30 ԭ���ø� 用脂肪族聚胺治疗综合症x的方法
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
EP1923064B1 (en) 2001-04-18 2017-06-28 Genzyme Corporation Use of amine polymer for lowering serum glucose
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
US7192609B2 (en) 2001-04-23 2007-03-20 Shire International Licensing B.V. Use of rare earth compounds for the prevention of kidney stone disease
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US20030113308A1 (en) * 2001-10-05 2003-06-19 Harmeet Sidhu Materials and methods for reducing oxalate concentrations in fluids
ATE389684T1 (de) * 2001-10-09 2008-04-15 Genzyme Corp Verfahren zum reinigen und trocknen von polymerhydrogelen
US6600011B2 (en) * 2001-10-09 2003-07-29 Genzyme Corporation Process for purification and drying of polymer hydrogels
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
KR101269766B1 (ko) 2004-03-30 2013-05-30 리립사, 인크. 이온 결합 중합체 및 이의 용도
EP1755655A4 (en) * 2004-05-07 2011-03-30 Oxthera Inc METHOD AND COMPOSITIONS FOR REDUCING OXALATE CONCENTRATIONS
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
WO2007027566A2 (en) 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
CA2622693C (en) 2005-09-15 2015-05-05 Genzyme Corporation Sachet formulation for amine polymers
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
WO2007070052A2 (en) * 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2007075447A2 (en) * 2005-12-16 2007-07-05 Oxthera, Inc. Compositions and methods for oxalate reduction
WO2007130463A2 (en) * 2006-05-05 2007-11-15 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
EP2043767B1 (en) 2006-07-14 2020-03-25 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
WO2008011047A2 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
CA2659081C (en) 2006-08-02 2018-01-16 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and use thereof
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
BRPI0716319A8 (pt) * 2006-10-25 2019-02-05 Aovatechnologies Inc método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano
JP2010508281A (ja) * 2006-10-26 2010-03-18 ウィスコンシン・アラムナイ・リサーチ・ファウンデイション リン酸塩吸収の低減方法
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
EP2114376A1 (en) * 2007-02-23 2009-11-11 Genzyme Corporation Amine polymer compositions
JP2010520285A (ja) * 2007-03-08 2010-06-10 ゲンズイメ コーポレーション スルホンポリマー組成物
WO2008113364A2 (en) * 2007-03-20 2008-09-25 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
EP2217215A1 (en) * 2007-12-14 2010-08-18 Genzyme Corporation Coated pharmaceutical compositions
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
WO2010123039A1 (ja) * 2009-04-21 2010-10-28 株式会社医学生物学研究所 生物学的材料の不動化を行うための組成物
WO2014113648A1 (en) 2013-01-18 2014-07-24 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
PE20151766A1 (es) * 2013-03-15 2015-12-11 Genzyme Corp Agentes quelantes de precursores de producto final de glicacion avanzada (age)
WO2014197806A2 (en) 2013-06-07 2014-12-11 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
US10435528B2 (en) 2013-09-17 2019-10-08 Aquanano Llc High-capacity anion exchange materials
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
AU2016244121B2 (en) 2015-04-02 2020-11-05 Orenzymes Llc High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
GB201718803D0 (en) * 2017-11-14 2017-12-27 Phoenix Molecular Pte Ltd Method for isolation of nucleic acids
WO2019236858A1 (en) * 2018-06-06 2019-12-12 The Board Of Trustees Of The University Of Illinois Zwitterionic biocompatible polymers, methods, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198396A (en) * 1974-07-03 1980-04-15 Warren-Teed Laboratories, Inc. Dissolution of gallstones
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
JPS60202869A (ja) * 1984-03-26 1985-10-14 Ajinomoto Co Inc 大環状ポリアミン誘導体及びその用途
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
US5244913A (en) * 1991-11-19 1993-09-14 Baxter International Inc. Compositions and methods for dissolving body calculi
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
CN1238789A (zh) * 1996-10-23 1999-12-15 陶氏化学公司 用于降低饮食中磷酸根或草酸根吸收的水溶性聚合物
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate

Also Published As

Publication number Publication date
AR016001A1 (es) 2001-05-30
JP2001521902A (ja) 2001-11-13
JP4452402B2 (ja) 2010-04-21
CA2349620A1 (en) 1999-05-14
ZA989671B (en) 1999-04-28
DE69833134D1 (de) 2006-03-30
EP1645278A3 (en) 2007-11-14
US6281252B1 (en) 2001-08-28
EP1645278A2 (en) 2006-04-12
CA2349620C (en) 2008-04-08
DE69833134T2 (de) 2006-08-10
WO1999022744A1 (en) 1999-05-14
EP1044008B1 (en) 2006-01-04
US6177478B1 (en) 2001-01-23
EP1044008A1 (en) 2000-10-18
TW585772B (en) 2004-05-01
US5985938A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
AU6477498A (en) Scale inhibitors
ZA989671B (en) Method of reducing oxalate
AU1408199A (en) Patient support surfaces
AU7552198A (en) Benzylamine derivatives
AU6873398A (en) Table construction
AUPO395396A0 (en) Benzamide derivatives
ZA98376B (en) Sulfamide-metalloprotease inhibitors
AU8262898A (en) Dental isolator
GB2321641B (en) Sulfamide-metalloprotease inhibitors
AU9317298A (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
AU5328198A (en) Work holding apparatus
AU8673598A (en) Neuraminidase inhibitors
AU7813598A (en) Betulinol derivatives
AU8038798A (en) Cis-substituted fluoromethylpyrrolidine derivatives
AU8333998A (en) New use of nociceptin
GB9815925D0 (en) HIV Intergrase inhibitors
AU6271098A (en) Hiv integrase inhibitors
AU7722698A (en) Portable holder
AU3119295A (en) Direct chip attach
HK1034035A (en) Use of aliphatic polymines for reducing oxalate
AU1691599A (en) Aliphatic derivatives
AU7427098A (en) Inhibitors of g-protein-beta/gamma subunit function
AU4541997A (en) Sportfishing outriggers
AU2716597A (en) Holding unit
AU7576798A (en) Sympathomimetic compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase